Genzyme Corp.

Upcoming decisions include a label expansion for Alnylam’s Amvuttra, a new siRNA therapy for hemophilia, and more

Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space

Plus: Amylyx gets a head of international markets, and updates from Heron, Breye, Alvotech and more

Plus: Flamingo hires a new CMO, and updates from Arkuda and GeneDx

With launches looming and chairman likely to retire, new CEO eyes shorter timelines to proof of concept, will mull bringing in assets via deals

Chris Viehbacher could reprioritize Biogen via BD, while David Epstein could get Seagen’s launches on track

Belgian biotech is applying lessons of past orphan drugs to Vyvgart’s launch

AZ unit finds entry point to gene therapy in $68M acquisition

Board chairs become key strategic hire as VCs put newco management teams in place

Rare disease company invested in a spinout of a non-profit that was making science decisions, not just writing checks